Related Experiment Videos
Chemoimmunotherapy of implanted murine bladder cancer
Urology
|March 1, 1983
Summary
This study explored intravesical mitomycin C (MMC) combined with systemic levamisole (Leva) for superficial bladder cancer. While not reducing tumor incidence alone, levamisole may enhance MMC therapy effectiveness.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Superficial bladder tumors often recur after chemotherapy.
- Adjuvant therapies are needed to improve treatment outcomes.
Purpose of the Study:
- To evaluate the efficacy of intravesical mitomycin C (MMC) combined with systemic levamisole (Leva) as an adjuvant therapy for superficial bladder cancer.
- To assess the impact of MMC and Leva on tumor incidence and spleen weight in a mouse model.
Main Methods:
- A mouse model of superficial bladder cancer was established using cauterization and tumor cell implantation.
- Mice were treated with normal saline (control), MMC, Leva, or MMC plus Leva.
- Chemotherapy (MMC) was administered intravesically, and immunotherapy (Leva) intraperitoneally.
Main Results:
- Treatment groups showed reduced bladder tumor incidence (50-63%) compared to the control group (91%).
- Levamisole and the combination therapy increased spleen weight, unlike MMC alone.
- Levamisole did not significantly reduce tumor incidence on its own.
Conclusions:
- Intravesical mitomycin C combined with systemic levamisole shows potential as an adjuvant therapy for superficial bladder cancer.
- Immunostimulators like levamisole may offer benefits when used concurrently with chemotherapy.